These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 21350858)
61. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203 [TBL] [Abstract][Full Text] [Related]
62. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Nalesnik MA; Jaffe R; Starzl TE; Demetris AJ; Porter K; Burnham JA; Makowka L; Ho M; Locker J Am J Pathol; 1988 Oct; 133(1):173-92. PubMed ID: 2845789 [TBL] [Abstract][Full Text] [Related]
63. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation. Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718 [TBL] [Abstract][Full Text] [Related]
64. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438 [TBL] [Abstract][Full Text] [Related]
65. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Terao T; Tsushima T; Fukumoto A; Kuzume A; Miura D; Narita K; Takeuchi M; Matsue K Int J Hematol; 2021 Jul; 114(1):136-140. PubMed ID: 33675520 [TBL] [Abstract][Full Text] [Related]
77. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Tanner JE; Alfieri C Transpl Infect Dis; 2001 Jun; 3(2):60-9. PubMed ID: 11395971 [TBL] [Abstract][Full Text] [Related]
78. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216 [TBL] [Abstract][Full Text] [Related]
79. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Nelson BP; Nalesnik MA; Bahler DW; Locker J; Fung JJ; Swerdlow SH Am J Surg Pathol; 2000 Mar; 24(3):375-85. PubMed ID: 10716151 [TBL] [Abstract][Full Text] [Related]
80. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Nalesnik MA Transpl Infect Dis; 2001 Jun; 3(2):88-96. PubMed ID: 11395974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]